BTG Share News (BTG)

London pre-open: FTSE set for small drop ahead of data

Following a fairly flat session in the US on Wednesday evening, the FTSE is set for a modest decline at Thursday's opening bell, as investors look ahead to a busy day of data and company news. City sources predict the FTSE 100 will open around eight points lower than the previous day's close of 6,

UK MORNING BRIEFING: CSR Soars On Bid Report; Xaar Falls On Outlook

BTG Says China Regulator Approves Liver Cancer Treatment Registration

Sector movers: Astrazeneca boosts pharma stocks on Pfizer return hopes

Astrazenca was leading the pharmaceuticals sector higher on Thursday on the back of speculation that US drug giant Pfizer could return with a fresh offer in the coming days. The reports lifted others in the sector higher in afternoon trading with peers such as Glaxosmithkline, Hikma and BTG making

Tuesday broker round-up UPDATE

Abderdeen Asset Management: Berenberg cuts target price from 530p to 510p and maintains a buy recommendation. African Barrick Gold: Numis takes target price from 260p to 330p upgrading from hold to buy. Anglo American: Deutsche Bank increases target price from 1590p to 1650p and reiterates a hold

UK BROKER RATINGS: Numis Raises GKN To Buy From Add

CORRECT: UK MORNING BRIEFING: GKN Leads FTSE 100 On Profit Increase

UK MORNING BRIEFING: GKN Leads FTSE 100 On Profit Increase

Land Securities director acquires 10,000 shares

Cressida Hogg, a Non-Executive Director of Land Securities, has spent £105,000 on 10,000 shares in the real estate investment trust. The purchase marks her only stake in the company. Meanwhile, Rolf Soderstrom, Chief Financial Officer at BTG has sold all of the 34,637 released under the group's

DIRECTOR DEALINGS: BTG Directors Exercise Options, Sell Shares

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

BTG reiterates full-year guidance

- FY revenue guidance unchanged - Trading in line - US investigating LC Bead Healthcare company BTG has left its full-year revenue guidance unchanged, saying trading has been in line with expectations. Full-year revenue is expected to be in the £330m to £345m range, despite the recent weakening of

UK MIDDAY BRIEFING: Ashley Foregoes Hard-Fought Share Bonus

UK WINNERS & LOSERS: Meggitt Tops FTSE 100 On Airshow Rumour

TOP NEWS: Meggitt Declines Comment On Rumour Putting It Atop FTSE 100